Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.76|
|52 Week High||US$7.01|
|52 Week Low||US$20.69|
|1 Month Change||-11.11%|
|3 Month Change||14.02%|
|1 Year Change||-31.94%|
|3 Year Change||271.10%|
|5 Year Change||n/a|
|Change since IPO||67.99%|
Recent News & Updates
Why Co-Diagnostics Is A Solid Covid-19 Play
Co-Diagnostics shares rallied after the company posted strong quarterly results. Total addressable market expanding. Stock steeply undervalued and scores a Seeking Alpha Quant Score of 'A' on key metrics.
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Co-Diagnostics, Inc. ( NASDAQ:CODX ) shareholders would be excited to see that the share price has had a great month...
|CODX||US Medical Equipment||US Market|
Return vs Industry: CODX underperformed the US Medical Equipment industry which returned 36.8% over the past year.
Return vs Market: CODX underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: CODX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CODX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes.
Co-Diagnostics Fundamentals Summary
|CODX fundamental statistics|
Is CODX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CODX income statement (TTM)|
|Cost of Revenue||US$15.91m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.60|
|Net Profit Margin||47.98%|
How did CODX perform over the long term?See historical performance and comparison
Is Co-Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CODX ($9.76) is trading below our estimate of fair value ($462.98)
Significantly Below Fair Value: CODX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CODX is good value based on its PE Ratio (6.1x) compared to the US Medical Equipment industry average (52.3x).
PE vs Market: CODX is good value based on its PE Ratio (6.1x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: CODX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: CODX is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (4.8x).
How is Co-Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CODX's earnings are forecast to decline over the next 3 years (-42.8% per year).
Earnings vs Market: CODX's earnings are forecast to decline over the next 3 years (-42.8% per year).
High Growth Earnings: CODX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: CODX's revenue is expected to decline over the next 3 years (-3.1% per year).
High Growth Revenue: CODX's revenue is forecast to decline over the next 3 years (-3.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CODX's Return on Equity is forecast to be high in 3 years time
How has Co-Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CODX has high quality earnings.
Growing Profit Margin: CODX's current net profit margins (48%) are higher than last year (40.6%).
Past Earnings Growth Analysis
Earnings Trend: CODX has become profitable over the past 5 years, growing earnings by 71.9% per year.
Accelerating Growth: CODX's earnings growth over the past year (342%) exceeds its 5-year average (71.9% per year).
Earnings vs Industry: CODX earnings growth over the past year (342%) exceeded the Medical Equipment industry 40.5%.
Return on Equity
High ROE: CODX's Return on Equity (53%) is considered outstanding.
How is Co-Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: CODX's short term assets ($90.3M) exceed its short term liabilities ($4.7M).
Long Term Liabilities: CODX's short term assets ($90.3M) exceed its long term liabilities ($794.6K).
Debt to Equity History and Analysis
Debt Level: CODX is debt free.
Reducing Debt: CODX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: CODX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CODX has no debt, therefore coverage of interest payments is not a concern.
What is Co-Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CODX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CODX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CODX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CODX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CODX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dwight Egan (68 yo)
Mr. Dwight H. Egan serves as the Chairman, Chief Executive Officer and President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment business...
CEO Compensation Analysis
Compensation vs Market: Dwight's total compensation ($USD1.46M) is above average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Dwight's compensation has increased by more than 20% in the past year.
Experienced Board: CODX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CODX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Co-Diagnostics, Inc.'s employee growth, exchange listings and data sources
- Name: Co-Diagnostics, Inc.
- Ticker: CODX
- Exchange: NasdaqCM
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$281.965m
- Shares outstanding: 28.89m
- Website: https://www.codiagnostics.com
Number of Employees
- Co-Diagnostics, Inc.
- 2401 South Foothill Drive
- Suite D
- Salt Lake City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 22:06|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.